Gastric cancer, version 2.2025 Guidelines

  


Authors: Ajani, J. A.; D’Amico, T. A.; Bentrem, D. J.; Corvera, C. U.; Das, P.; Enzinger, P. C.; Enzler, T.; Gerdes, H.; Gibson, M. K.; Grierson, P.; Gupta, G.; Hofstetter, W. L.; Ilson, D. H.; Jalal, S.; Kim, S.; Kleinberg, L. R.; Klempner, S.; Lacy, J.; Lee, B.; Licciardi, F.; Lloyd, S.; Ly, Q. P.; Matsukuma, K.; McNamara, M.; Merkow, R. P.; Miller, A. M.; Mukherjee, S.; Mulcahy, M. F.; Perry, K. A.; Pimiento, J. M.; Reddi, D. M.; Reznik, S.; Roses, R. E.; Strong, V. E.; Su, S.; Uboha, N.; Wainberg, Z. A.; Willett, C. G.; Woo, Y.; Yoon, H. H.; McMillian, N. R.; Stein, M.
Title: Gastric cancer, version 2.2025
Abstract: Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease. © 2025 Harborside Press. All rights reserved.
Keywords: unclassified drug; mortality; cancer recurrence; advanced cancer; systemic therapy; drug approval; postoperative care; cancer staging; cancer diagnosis; neoplasm staging; biological marker; gene overexpression; metastasis; peritoneum cancer; epidermal growth factor receptor 2; practice guideline; pathology; oncology; tumor marker; cancer therapy; histology; mismatch repair; diagnosis; clinical evaluation; medical oncology; stomach cancer; inoperable cancer; clinical practice guideline; trastuzumab; stomach neoplasms; therapy; chemoradiotherapy; stomach tumor; programmed death 1 receptor; molecularly targeted therapy; second-line treatment; procedures; endoscopic submucosal dissection; first-line treatment; cancer prognosis; dabrafenib; trametinib; hyperthermic intraperitoneal chemotherapy; nivolumab; ramucirumab; humans; prognosis; human; article; pembrolizumab; entrectinib; treatment guideline; liquid biopsy; biomarkers, tumor; larotrectinib; tumor mutational burden; repotrectinib; trastuzumab deruxtecan; selpercatinib; dostarlimab; tislelizumab; zolbetuximab; tight junction protein; claudin 18 isoform 2
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 23
Issue: 5
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2025-05-01
Start Page: 169
End Page: 191
Language: English
DOI: 10.6004/jnccn.2025.0022
PUBMED: 40341199
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-105004862556&doi=10.6004%2fjnccn.2025.0022&partnerID=40&md5=916c6da87eb57715519bbe051029bb60
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Hans Gerdes
    176 Gerdes
  2. Vivian Strong
    265 Strong
  3. David H Ilson
    433 Ilson
Related MSK Work